Seoul, South Korea

Heui-Young Ryu

USPTO Granted Patents = 1 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Heui-Young Ryu: Innovator in Retinal Dystrophies Treatment

Introduction

Heui-Young Ryu is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of retinal dystrophies. His innovative work focuses on utilizing specific active ingredients to combat retinal degeneration and preserve visual function.

Latest Patents

Heui-Young Ryu holds a patent for a pharmaceutical composition aimed at treating retinal dystrophies. The patent describes a composition that includes Nkx3.2 and its fragments as active ingredients. This composition effectively inhibits retinal degeneration caused by oxidative stress and helps maintain visual function. Additionally, it prevents cell death in retinal pigment epithelial cells and inhibits choroidal neovascularization and retinal edema. This groundbreaking work positions his composition as a potential treatment for retinal dystrophies and macular degeneration.

Career Highlights

Heui-Young Ryu is associated with Icm Co., Ltd., where he continues to advance his research and development efforts. His dedication to innovation in the pharmaceutical industry has led to significant advancements in the treatment of eye diseases.

Collaborations

Heui-Young Ryu collaborates with notable colleagues, including Dae-Won Kim and Young-Na Yum. Their combined expertise contributes to the ongoing research and development of effective treatments for retinal conditions.

Conclusion

Heui-Young Ryu's contributions to the field of pharmaceuticals, particularly in treating retinal dystrophies, highlight his innovative spirit and commitment to improving visual health. His work has the potential to make a significant impact on the lives of individuals suffering from retinal diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…